Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach. - Overgaard RV; Birkhan O; Rathor N; Sparsø T; Strathe A; Wharton S; Rubino D (Diabetes, obesity & metabolism, 2026)